“Patient Preference for Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Foam or Topical Suspension Vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s26, https://doi.org/10.25251/skin.1.supp.25.